BSLN — Basilea Pharmaceutica AG Allschwil Cashflow Statement
0.000.00%
Last trade - 00:00- CH₣668.55m
- CH₣584.19m
- CH₣232.38m
- 87
- 43
- 78
- 84
Annual cashflow statement for Basilea Pharmaceutica AG Allschwil, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.83 | 12.1 | 10.5 | 77.6 | 40.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.84 | 5.54 | 6.53 | 6.08 | 5.74 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -31.8 | -11.7 | -4.32 | 6.29 | 8.77 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -32 | 7.06 | 14.2 | 74.4 | 62.1 |
| Capital Expenditures | -0.86 | -3.3 | -1.03 | -1.79 | -2.86 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 4.43 | 95 | 0 | 0.781 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 3.58 | 91.6 | -1.03 | -1.01 | -2.86 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.6 | -45.2 | -57.3 | -13.2 | -21.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.3 | 53.6 | -44.2 | 60.2 | 37.8 |